Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock Plans and Stock-Based Compensation (Tables)

Stock Plans and Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2012

Stock Plans and Stock-Based Compensation [Abstract]

Assumptions used to calculate fair value for stock based awards

The following assumptions were used:


Stock option plans	2012		2011
Exercise price		$4.75–$7.84		$1.37–$6.00
Expected stock price volatility		87.3%–114.3%		87.5%–92.8%
Risk free rate of interest		0.16%–2.23%		1.17%–2.56%
Expected life of options		2 years–10 years		6 years–10 years

Components of stock-based compensation expense

The following table summarizes the stock-based compensation expense from stock option, employee stock purchase programs and restricted common stock awards and warrants for the years ended December 31, 2012, 2011 and 2010, and from the period June 28, 2006 (Date of Inception) to date:


($ in thousands)	2012		2011		2010		Period from June 28, 2006 (Date of Inception) to December 31, 2012
Employee awards	$	2,408	$	520	$	215	$	3,206
Non-employee awards		664		662		2,114		3,413
Non-employee warrants		566		287		—		893

Total compensation expense	$	3,638	$	1,469	$	2,329	$	7,512

Summary of stock option activity

The following table summarizes stock option activity:


	Outstanding Options						Weighted Average Remaining Contractual Life (in years)
($ in thousands except per share amounts)	Number of Shares		Weighted Average Exercise Price		Total Weighted Average Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
Outstanding at December 31, 2011		1,814,070	$	2.17	$	7,852		9.2
Options granted		730,000	$	6.52
Options exercised		—
Options forfeited		—
Options cancelled		25,000	$	7.84

Outstanding at December 31, 2012		2,519,070	$	3.37	$	2,860		8.54

Options vested and expected to vest		2,519,070	$	3.37	$	2,860		8.54

Options vested and exercisable		856,047	$	1.95	$	2,193		8.09